Spotlight On ATTR-CM

Core Disease Understanding (8 articles)

Pathophysiology, epidemiology, variants, and natural history

• ATTR-CM Epidemiology: Underdiagnosis and Case Ascertainment
• TTR Pathogenic Variant in ATTR-CM: Etiology, Penetrance, and Family Risk
• Risk Factors in ATTR-CM: Susceptibility, Pattern Recognition, and Confounders
• Natural History in ATTR-CM: Progression, Delay, and Clinical Course
• ATTR-CM Epidemiology: Prevalence, Incidence, and Recognition Trends
• Pathophysiology in ATTR-CM: Infiltration, Remodeling, and Stage-Dependent Effect
• ATTR-CM: A Progressive Amyloid Heart Failure Syndrome
• ATTRv vs ATTRwt: Hereditary and Wild-Type ATTR-CM

Diagnosis and Confirmation (17 articles)

Red flags, imaging, labs, staging, and exclusion of AL amyloidosis

• ATTR-CM Imaging and Tools: Coordinated Pathways Over Isolated Testing
• Pediatric ATTR-CM: Diagnostic Considerations in a Rare Disease
• ATTR-CM Guidance: Principles of Noninvasive Diagnosis
• Cardiac MRI in ATTR-CM: Role in Tissue Characterization and Diagnostic Workup
• Serum Free Light Chains in ATTR-CM: An Exclusion Signal, Not a Diagnosis
• Serum and Urine Immunofixation Electrophoresis in ATTR-CM: Exclusion Before Confirmation
• Echocardiography in ATTR-CM: Early Phenotype, Limited Specificity
• Diagnostic Criteria in ATTR-CM: Interpreting the Workup
• Biomarkers in ATTR-CM: Supportive Signal, Not Standalone Diagnosis
• Differential Diagnosis in ATTR-CM: Excluding AL and Reading the Phenotype
• Screening and Early Detection in ATTR-CM: Sequencing the Workup
• Differential Diagnosis in ATTR-CM: Pattern Recognition and Exclusion Logic
• Differential Diagnosis in ATTR-CM: 99mTc-PYP Scintigraphy and Diagnostic Workup
• ATTR-CM Red Flags: Cardiac and Extracardiac Clues
• ATTR-CM Genetic Testing, Counseling, and Cascade Screening
• ATTR-CM Staging and Risk Stratification: NAC, Mayo, NYHA
• ATTR-CM Endomyocardial Biopsy and Histology

Clinical Management and Follow-Up (11 articles)

Monitoring, comorbidities, coordination, and continuity

• ATTR-CM Clinical Management Depends on Staying in the Fight
• ATTR-CM and Comorbid Conditions: Diagnostic and Management Challenges
• Geriatric ATTR-CM: Diagnostic and Management Considerations in Older Adults
• Adverse-Effect Management in ATTR-CM: Tolerance, Monitoring, and Continuity
• Advanced ATTR-CM Management: Narrow Reserve, Narrow Margin
• Multidisciplinary ATTR-CM Care: The Importance of Coordinated Care
• Monitoring in ATTR-CM: Follow Trends, Not Single Signals
• ATTR-CM Care Coordination: Closing the Handoff Gaps
• ATTR-CM Arrhythmia Management and Heart Failure Co-Management
• ATTR-CM Patient Education and Shared Decision-Making
• ATTR-CM Palliative Care and Advance Care Planning

Treatment Landscape (7 articles)

Mechanisms, sequencing, safety, and first-line decisions

• ATTR-CM Treatment Safety: Product-Specific Considerations
• The ATTR-CM Therapeutic Landscape: Mechanisms of Action and Treatment Considerations
• First-Line Therapy in ATTR-CM: Subtype Confirmation and Treatment Continuity
• Targeted ATTR-CM Therapy Is About Trajectory, Not Rescue
• Treatment Crossroads in ATTR-CM: Stage, Persistence, and Practical Fit
• Second-Line ATTR-CM Care: A Reassessment-Based Approach
• Treatment Sequencing in ATTR-CM: Stage, Feasibility, and Persistence

Treatment with Tafamidis (7 articles)

Evidence, prescribing, persistence, and refractory disease questions

• Refractory ATTR-CM: Persistent Burden Is Not Always Drug Failure
• Adherence and Persistence in ATTR-CM: Continuity Over Time
• Tafamidis in ATTR-CM: Established, Chronic, and Not Acute Rescue
• How Multidisciplinary Care Supports Tafamidis in ATTR-CM
• Refractory Disease in ATTR-CM: Tafamidis and Treatment Decisions
• Tafamidis Prescribing Updates in ATTR-CM: Long-Term Therapy Following Appropriate Diagnosis
• Tafamidis Evidence in ATTR-CM: What Holds Up in Practice

Treatment with Acoramidis (5 articles)

Evidence, sequencing, and label questions

• Acoramidis Evidence in ATTR-CM: Clinical Interpretation Within Appropriate Boundaries
• Acoramidis in Pregnancy: Sparse Human Data in ATTR-CM
• Acoramidis in ATTR-CM: Targeted Stabilization, Not Reversal
• Acoramidis Prescribing Updates in ATTR-CM: What the Label Clarifies
• Acoramidis Sequencing in ATTR-CM: Start With Confirmation

Emerging and Alternative Therapies (5 articles)

Gene silencers, pipeline signals, and exploratory evidence

• ATTR-CM Preclinical Research: Mechanistic Signal and Translational Limits
• Emerging ATTR-CM Therapies: Mechanisms, Signals, and Limits
• Precision Biotech in ATTR-CM: Diagnostic Confidence and Clinical Fit
• Diflunisal in ATTR-CM: Practical Role and Evidence Limits
• ATTR-CM Gene Silencers: Patisiran, Eplontersen, and Combination Therapy

Evidence, Trials, and Regulation (9 articles)

Trials, real-world evidence, labels, and guidelines

• Real-World Evidence in ATTR-CM: Interpreting Treatment Outcomes in Routine Clinical Practice
• ATTR-CM Implementation Evidence: Real-World Care Provides the Missing Context
• Understanding Conflicting ATTR-CM Evidence: The Influence of Study Population and Study Design
• Landmark ATTR-CM Evidence: Slowing Progression, Not Reversing It
• FDA Labels in ATTR-CM: Approval Is Bounded by Phenotype
• Ongoing Trials in ATTR-CM: What Current Study Design May Clarify
• Primary Research in ATTR-CM: What the Current Evidence Actually Shows
• ATTR-CM Guidelines and Regulation: Confirm First, Treat Within Label
• Head-to-Head Trials in ATTR-CM: Comparative Signal Without Simple Hierarchy

Outcomes, Burden, and Complications (7 articles)

Prognosis, mortality, hospitalization, and patient burden

• Mortality in ATTR-CM: Disease Severity Determines Risk
• Prognostic Indicators in Integrating Biomarkers, Structure, and Clinical Context
• Chronic ATTR-CM Complications Build Before Crisis Hits
• Acute ATTR-CM Complications: Recognizing Clinical Deterioration
• Patient Burden in ATTR-CM: Symptoms, Function, and Caregiver Impact
• Hospitalization Triggers in ATTR-CM: Warning Signs and Risk
• Advanced ATTR-CM Complications: A Pattern of Progressive Physiological Instability

Access, Equity, and System Friction (6 articles)

Cost, coverage, disparities, and access delays

• ATTR-CM Disparities: Recognition, Referral, and Continuity of Specialty Care
• ATTR-CM Access Ethics: When Access Failure Becomes Clinical Failure
• ATTR-CM Access Delays: Clinical Significance of Delayed Initiation and Interrupted Treatment
• ATTR-CM Equity Problems Show Up Before Treatment Starts
• ATTR-CM Access Policy Begins With Diagnostic Proof
• Cost and Access Management in ATTR-CM: Persistence, Workflow, and Barriers

Technology, AI, and Workflow (6 articles)

Clinical AI, digital health, devices, and health IT

• ATTR-CM Medtech: Workflow Support Beats Feature Hype
• ATTR-CM as a Learning Health System: Continuity Creates Signal
• Digital Health in ATTR-CM: Remote Care That Protects Continuity
• Devices and Interventional Technology in ATTR-CM: Clinical Role and Limits
• Clinical AI in ATTR-CM: Decision Support, Workflow, and Limits
• Health IT and Cyber Resilience in ATTR-CM: Infrastructure for Longitudinal Care

Case-Based and Editorial Watchpoints (7 articles)

Case framing and editorial signals on where practice is moving

• Emerging Watchpoints in ATTR-CM: Reading Exploratory Signals Carefully
• Case-Based Framing in ATTR-CM: When Suspicion Becomes a Treatment Decision
• ATTR-CM Signal Editorial: The Early Decision Point Arrives Now
• Atypical Case Signal in ATTR-CM: When the Pattern Refuses to Behave Normally
• ATTR-CM Heterogeneity: How Evenly Benefit Travels
• ATTR-CM Watchpoint: Early Start, Real Persistence
• Shifting Standards in ATTR-CM: Earlier Recognition, Longer Follow-Through

What is ATTR-CM?

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart-failure syndrome caused by deposition of misfolded transthyretin protein in the myocardium. It's increasingly recognized and treatable when identified early.

How is ATTR-CM diagnosed?

Diagnosis combines a compatible phenotype, exclusion of AL amyloidosis (serum free light chains plus immunofixation), and 99mTc-PYP scintigraphy; genetic testing distinguishes hereditary from wild-type disease. For more information, see the Diagnosis and Confirmation cluster.

What treatments are available for ATTR-CM?

Transthyretin stabilizers (tafamidis, acoramidis) are the established disease-modifying options, with emerging gene-silencing and amyloid-depleting strategies under study. For more information, see the Treatment Landscape, Treatment with Tafamidis, and Treatment with Acoramidis clusters.

Why does early diagnosis matter?

ATTR-CM is progressive, and stabilizers slow rather than reverse damage, so the window to modify the disease narrows as myocardial involvement advances. For more information, see the Outcomes, Burden, and Complications cluster.